Implantable CGM Use Improves Glycemic Control in CGM Naive Patients
10/17/2023
|
|
Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study
09/09/2021
|
|
Ascensia Diabetes Care launches patient assistance program to provide broader access to Eversense Continuous Glucose Monitoring System
07/20/2021
|
|
Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance
07/01/2021
|
|
The PROMISE Study: An Evaluation of the Safety and Accuracy of the Next Generation 180-Day Long-term Implantable Eversense CGM System
06/27/2021
|
|
The PROMISE Study: An Evaluation of the Safety and Accuracy of the Next Generation 180-Day Long-term Implantable Eversense CGM System
06/03/2021
|
|
2020 ATTD: Longitudinal Analysis of Real-World Performance of an Implantable Continuous Glucose Sensor Over Multiple Sensor Insertion and Removal Cycles
02/23/2020
|
|
2020 ATTD: Percent of Patients with Targeted Time in Range and Time in Hypoglycemia with the Eversense CGM System
02/23/2020
|
|
2020 ATTD: Correlation Between Time in Range and Glucose Management Indicator with the Eversense CGM System
02/23/2020
|
|
2020 ATTD: The Glycemic Outcomes of the Eversense CGM System in an Expanded Cohort of 582 Real-World US Commercial Users
02/23/2020
|
|